
Sign up to save your podcasts
Or


Today we're joined by Dr. Joshua Britton, founder and CEO of Debut Biotech, a cell-free biomanufacturing company. Josh gives us a crash course on synthetic biology and biomanufacturing, walking us through the various methods and promise of this industry that may very well shift industrial production away from fossil fuels. We also get into some of the founding story of Debut, including how Cantos' investment in Debut came to be...hint: it had to do with a cold message.
Shownotes:
Cantos analysts Amee and Andrew dive into their top predictions for what deep tech might see in 2022.
Shownotes:
Today we're joined by Anna Perdrix Rossell and George Foot of Sixfold Bioscience, co-founders of Sixfold Bioscience, a UK based biotech company using computation and advanced chemistry to engineer highly programmable constructs that make the delivery of RNA therapeutics predictable and precise. Sixfold's technology expands the purview of RNA therapeutics from vaccines to all diseases, starting with cancer. In our conversation, we discuss the challenge of RNA delivery, what it's like starting a biotech company totally from scratch (no academic spinout or venture incubation), how to hire a diverse team, and promising areas of biotechnology.
Shownotes:
Today we're joined by Vanessa Clark and William Kowalski, cofounders of Atomos Space, an aerospace company transforming how we operate in space with orbital transfer vehicles. In our conversation, we discuss the importance of orbital transfer vehicles or "space taxis", regulations when operating in space, and the early days of Atomos. We hope you enjoy our conversation with Vanessa and William.
Shownotes:
From the publisher's feed